Skip to main content
SpringerLink
Log in

Lifelong therapy required for primary pulmonary hypertension, a rare but serious disease

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. De Backer TLM, Smedema J-P, Carlier SG. Current management of primary pulmonary hypertension. Biodrugs 2001; 15(12): 801–17

    Article  PubMed  Google Scholar 

  2. Wanstall JC, Jeffery TK. Recognition and management of pulmonary hypertension. Drugs 1998 Dec; 56(6): 989–1007

    Article  PubMed  CAS  Google Scholar 

  3. Rubin LJ. Primary pulmonary hypertension. Chest 1993; 104(1): 236–50

    Article  PubMed  CAS  Google Scholar 

  4. D’Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991; 115(5): 343–9

    PubMed  Google Scholar 

  5. Fuster V, Steele PM, Edwards WD, et al. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984; 70(4): 580–7

    Article  PubMed  CAS  Google Scholar 

  6. Klings ES, Farber HW. Current management of primary pulmonary hypertension. Drugs 2001; 61(13): 1945–56

    Article  PubMed  CAS  Google Scholar 

  7. Gertner, HP. Pulmonary hypertension ‘Plexogenic pulmonary arteriopathy’ and the appetite suppressant drug aminorex: post or proctor. Bull Eur Physiopathol Respir 1979; 15: 897–923

    Google Scholar 

  8. Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 335(9): 609–16

    Article  PubMed  CAS  Google Scholar 

  9. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327(2): 76–81

    Article  PubMed  CAS  Google Scholar 

  10. Gaine SP, Rubin LJ. Medical and surgical treatment options for pulmonary hypertension. Am J Med Sci 1998; 315(3): 179–84

    Article  PubMed  CAS  Google Scholar 

  11. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997; 336: 111–7

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lifelong therapy required for primary pulmonary hypertension, a rare but serious disease. Drugs Ther. Perspect 18, 17–20 (2002). https://doi.org/10.2165/00042310-200218110-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200218110-00006

Keywords

Search

Navigation